Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 20, 2017
Issued Date -
N/A
app pub date -
Jan 10, 2014
filing date -
Jan 10, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2014 Application Filing Year
- A61K Class
- 14144 Applications Filed
- 11600 Patents Issued To-Date
- 82.02 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 4 Citation Count
- A61K Class
- 45.09 % this patent is cited more than
- 8 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Dec 20, 2024 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Dec 20, 2028 |
